

Evan J. Vickers proposes the following substitute bill:

**Medication Amendments**

2025 GENERAL SESSION

STATE OF UTAH

**Chief Sponsor: Evan J. Vickers**

House Sponsor: Steve Eliason

---

---

**LONG TITLE**

**General Description:**

This bill addresses participation in a federal drug discount program.

**Highlighted Provisions:**

This bill:

- defines terms;
- prohibits a pharmaceutical manufacturer from restricting, prohibiting, or otherwise interfering with a 340B entity's ability to:
  - acquire a 340B drug; or
  - participate in the 340B drug discount program;
- permits the Public Employees' Benefit and Insurance Program (program) to adjust the program's business practices to mitigate any resulting financial impacts;
- permits a manufacturer to request certain claim information from 340B entities; and
- requires 340B entities to submit information to the Insurance Department.

**Money Appropriated in this Bill:**

None

**Other Special Clauses:**

None

**Utah Code Sections Affected:**

ENACTS:

**31A-46-311**, Utah Code Annotated 1953

**31A-46-312**, Utah Code Annotated 1953

---

---

*Be it enacted by the Legislature of the state of Utah:*

Section 1. Section **31A-46-311** is enacted to read:

**31A-46-311 . Protection of pharmacy discount drug market.**

- (1) As used in this section, "manufacturer" means a pharmaceutical manufacturer, including an agent or affiliate of a pharmaceutical manufacturer.
- (2) A manufacturer may not:
- (a) directly or indirectly, restrict or prohibit:
    - (i) a pharmacy from contracting with a 340B entity, including by denying the pharmacy access to a drug that is manufactured by the manufacturer;
    - (ii) a 340B entity from contracting with a pharmacy, including by denying the 340B entity access to a drug that is manufactured by the manufacturer;
    - (iii) the acquisition, dispensing, or delivery of a 340B drug to any location authorized by a 340B entity to receive the drug, unless prohibited by federal law; or
    - (iv) a 340B entity from receiving 340B drug discount program pricing for a 340B drug, including by imposing a time limitation on a 340B entity to replenish or submit a claim for a 340B drug;
  - (b) directly or indirectly:
    - (i) require a 340B entity to purchase a 340B drug from a supplier if the manufacturer would otherwise permit the 340B entity to purchase a drug that is not a 340B drug from the supplier; or
    - (ii) require a 340B entity to submit any claim data, utilization data, or information about a 340B entity's contracts with a third party as a condition for allowing the acquisition of a 340B drug by, or delivery of a 340B drug to, a 340B entity, unless the data or information sharing is required by federal law; or
  - (c) interfere with:
    - (i) a contract between a pharmacy and a 340B entity; or
    - (ii) the ability of a pharmacy and a 340B entity to enter into a contract.
- (3) The Public Employees' Benefit and Insurance Program created in Section 49-20-103 may adjust the program's business practices to mitigate any financial impacts resulting from this section.
- (4) Nothing in this section is to be construed to conflict with federal law.

Section 2. Section **31A-46-312** is enacted to read:

**31A-46-312 . Claim information sharing and use -- 340B entity public reporting.**

- (1) As used in this section:
- (a) "Bad debt" means the cost incurred by a participating 340B entity for providing health care services to a patient for which the participating 340B entity does not receive payment.

(b) "Claim information" means information that is:

(i) described in Subsection (2); and

(ii) related to a claim for a 340B drug that is:

(A) dispensed by a contract pharmacy; and

(B) manufactured by a single pharmaceutical manufacturer.

(c) "Contract pharmacy" means a pharmacy contracting with an entity participating in the 340B drug discount program to dispense drugs purchased through the 340B drug discount program.

(d) § → " ← § Financial assistance" means the cost incurred by a participating 340B entity for providing health care services to a patient at a reduced cost or no cost.

(e) "Participating 340B entity" means a 340B entity that is a hospital described in 42 U.S.C. Sec. 256b(a)(4)(L).

(f) Uncompensated care means the sum of a participating 340B entity's bad debt and financial assistance.

(2) § → A ← § pharmaceutical manufacturer may request from a participating 340B entity the following claim information:

(a) prescription number;

(b) prescribed date;

(c) fill date;

(d) national drug code;

(e) quantity;

(f) pharmacy identification; and

(g) 340B covered entity identification.

(3) A participating 340B entity that receives a request from a pharmaceutical manufacturer as described in Subsection (2) shall provide to the pharmaceutical manufacturer the requested claim information.

(4)(a) A pharmaceutical manufacturer may only use claim information received under this section to identify a rebate for an insurer or a third party administrator that is ineligible for payment under the pharmaceutical manufacturers policy.

(b) A pharmaceutical manufacturer may not use claim information received under this section to:

(i) establish restrictions or limitations on a participating 340B entity's ability to

- 95           purchase a 340B drug, including by establishing:
- 96           (A) allocations on purchasing based on the number of claims for which the
- 97           participating 340B entity provides claim information; or
- 98           (B) time limits for a participating 340B entity to replenish or replace inventory of
- 99           a 340B drug;
- 100          (ii) recoup from a participating 340B entity a discount for a 340B drug;
- 101          (iii) discriminate against, lower the reimbursement for, or impose any separate
- 102          condition on a participating 340B entity; or
- 103          (iv) take any other action that is not expressly authorized under this part.
- 104          (5)(a) Beginning on July 1, 2026, on or before July 1 each year, a participating 340B
- 105          entity shall provide the following to the department in a form and manner determined
- 106          by the department:
- 107                (i) the name of the participating 340B entity;
- 108                (ii) a copy of the participating 340B entity's annual 340B program recertification;
- 109                (iii) if the participating 340B entity is required to conduct a community health needs
- 110                assessment under Section 501(r)(3)(A), Internal Revenue Code, a copy of the
- 111                participating 340B entity's most recent community health needs assessment;
- 112                (iv) a statement that the participating 340B entity is in compliance with the 340B
- 113                drug discount program;
- 114                (v) the total number of contract pharmacies with which the participating 340B entity
- 115                contracts;
- 116                (vi) the total number of contract pharmacies located out-of-state and the states in
- 117                which out-of-state contract pharmacies; and
- 118                (vii) for the prior year:
- 119                      (A) a description of the impact of the 340B drug discount program on the patients
- 120                      and community served by the participating 340B entity;
- 121                      (B) the total operating costs of the participating 340B entity;
- 122                      (C) the total uncompensated care provided by the participating 340B entity; and
- 123                      (D) the total number of prescriptions and the percentage of the participating 340B
- 124                      entity's prescriptions filled at contract pharmacies.
- 125          (b) An officer of the participating 340B entity shall certify the completeness and
- 126          accuracy of the information submitted in accordance with Subsection (5)(a).
- 127          (c)(i) The department shall use the information described in Subsection (5)(a) to
- 128          prepare a report detailing aggregate information received from a participating

129           340B entity.

130           (ii) The department shall submit the report described in Subsection (5)(c)(i) to the

131           Health and Human Services Interim Committee on or before October 1, 2026.

132           (iii) The department shall post the report described in Subsection (5)(c)(ii) on a

133           publicly accessible website.

134    (6) Nothing in this section shall be construed to conflict with federal law.

135           Section 3. **Effective Date.**

136    This bill takes effect on May 7, 2025.